ABSTRACT

Intravesical BCG treatment has been used over 3 decades in the treatment of non-muscle invasive bladder cancer. Although the exact mechanism of its action is not clear, its clinical efficiency has been proven. Numerous clinical trials are still trying to answer; which tumoral lesions this drug should be used for, which dosage is enough, which maintanence should be chosen and how long it should be continued. In this article the answers of these questions, with the current evidence, are summarised.